期刊
BIOTECHNOLOGY ADVANCES
卷 32, 期 4, 页码 761-777出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biotechadv.2013.10.013
关键词
Nanotechnology; Nanomedicine; Targeted drug delivery system; Cancer metastasis therapy; Nanoparticle platform
资金
- Fuzhou University Start-up Fund [033084]
- Chinese National Science Foundation [81201709, 81102388, 81273548]
- National Science Foundation for Fostering Talents in Basic Research of China [J1103303]
- Science and Technology Development Foundation of Fuzhou University [2013-XQ-8, 2013-XQ-9]
Traditional chemotherapy used today at clinics is mainly inherited from the thinking and designs made four decades ago when the Cancer War was declared. The potency of those chemotherapy drugs on in-vitro cancer cells is clearly demonstrated at even nanomolar levels. However, due to their non-specific effects in the body on normal tissues, these drugs cause toxicity, deteriorate patient's life quality, weaken the host immunosurveillance system, and result in an irreversible damage to human's own recovery power. Owing to their unique physical and biological properties, nanotechnology-based chemotherapies seem to have an ability to specifically and safely reach tumor foci with enhanced efficacy and low toxicity. Herein, we comprehensively examine the current nanotechnology-based pharmaceutical platforms and strategies for intelligent design of new nanomedicines based on targeted drug delivery system (TDDS) for cancer metastasis treatment, analyze the pros and cons of nanomedicines versus traditional chemotherapy, and evaluate the importance that nanomaterials can bring in to significantly improve cancer metastasis treatment. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据